China Biologic Products Holdings, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China , today announced that the Company plans to release its first quarter 2020 financial results on Wednesday, May 20, 2020 after the market closes. The Company’s manage
|
BEIJING, China, May 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its first quarter 2020 financial results on Wednesday, May 20, 2020 after the market closes. The Company's management will hold a conference call at 7:30 a.m. ET on Thursday, May 21, 2020, which is 7:30 p.m. Beijing Time on May 21, 2020, to discuss first quarter 2020 results. Listeners may access the call by dialing:
A telephone replay will be available one hour after the conclusion of the conference call through May 28, 2020. The dial-in details are:
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/. About China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged in the sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com. Contact: China Biologic Products Holdings, Inc. The Foote Group
SOURCE China Biologic Products Holdings, Inc. |
||||||||||||||||
Company Codes: NASDAQ-NMS:CBPO |
View original content:
